Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals
Aref, H., Ahmed, M., Emara, A., Rezk, S., Abdelaziz, H. (2020). Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals. EKB Journal Management System, 79(1), 503-508. doi: 10.21608/ejhm.2020.84074
Hayam Aref; Mostafa Ahmed; Ahmed Abdelmoniem Emara; Salma Fathy Rezk; Haitham Ezzat Abdelaziz. "Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals". EKB Journal Management System, 79, 1, 2020, 503-508. doi: 10.21608/ejhm.2020.84074
Aref, H., Ahmed, M., Emara, A., Rezk, S., Abdelaziz, H. (2020). 'Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals', EKB Journal Management System, 79(1), pp. 503-508. doi: 10.21608/ejhm.2020.84074
Aref, H., Ahmed, M., Emara, A., Rezk, S., Abdelaziz, H. Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals. EKB Journal Management System, 2020; 79(1): 503-508. doi: 10.21608/ejhm.2020.84074

Incidence of Acute Kidney Injury in HCV Infected Patients Receiving Direct-Acting Antivirals

The Egyptian Journal of Hospital Medicine
Article 24, Volume 79, Issue 1, April 2020, Page 503-508  XML PDF (452.57 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2020.84074
View on SCiNiTO View on SCiNiTO
Authors
Hayam Aref1; Mostafa Ahmed2; Ahmed Abdelmoniem Emara email 1; Salma Fathy Rezk1; Haitham Ezzat Abdelaziz1
1Department of Internal Medicine and Nephrology, Ain Shams University, Cairo, Egypt
2Kobry El Kobba Military Hospital, Cairo, Egypt
Abstract
Background: Egypt had high burden of HCV infection worldwide. The new direct-acting antivirals (DAAs) can target almost all steps of HCV life cycle. Objective: Study of the incidence of acute kidney injury (AKI) in HCV infected patients receiving DAAs. Patients and methods: A prospective study that was conducted in the Virology Clinic in Kobry El-Koba Military Hospital on 63 male patients who were eligible to treatment by DAAs, who received treatment with sofosbuvir, daclatasvir and ribavirin combination. They were divided into Group A: 33 patients with eGFR > 90 ml/min and Group B: 30 patients with chronic kidney disease (CKD) stage II-III (eGFR<90 and >30 mL/min). The fluctuations in serum creatinine and eGFR were measured while on-therapy and for 3 months follow up after end of treatment. Results: total of 63 male patients, treatment-naive were included. Group A (33 patients) with eGFR > 90 mL/min. Group B (30 patients) with eGFR < 90 mL/min. There was a significant difference between different readings of serum creatinine in both groups on therapy and on follow up during the next 3 months after the end of therapy. The incidence of AKI was more observed in patients with eGFR > 90 ml/min in comparison with those with eGFR < 90 ml/min and >45 ml/min, but with no statistical significance. Conclusion: AKI events during and after end of therapy with DAAs were observed especially in patients with normal baseline serum creatinine. Patients with CKD stage II-III experienced improvement in their kidney functions during and after end of therapy. 
Keywords
Hepatitis C virus; Direct acting new antiviral drugs; Acute kidney injury
Statistics
Article View: 198
PDF Download: 454